In 2016, the WHO classification for CNS tumors incorporated not only light microscopy, immunohistochemical lineage-associated proteins, and ultrastructural characteristics, but also a few molecular markers, namely RELA-fusion ependymoma, to enhance the diagnostic and prognostic utility of this classification strategy [1]. This evidence concerns the gene RELA and ependymoma.